Capstone Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Capstone Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$255K	Sell	5,018 -130	-3%	-$6.05K	0.01%	1376
2017 Q1	$207K	Buy	5,148 +480	+10%	+$21.6K	0.01%	1519
2016 Q4	$223K	Buy	+4,668	New	+$185K	0.01%	1509
2016 Q1	–	Sell	-4,498	Closed	-$279K	–	1588
2015 Q4	$279K	Buy	+4,498	New	+$243K	0.01%	1325
2014 Q1	–	Sell	-5,995	Closed	-$239K	–	1787
2013 Q4	$239K	Sell	5,995 -5,982	-50%	-$213K	0.01%	1671
2013 Q3	$450K	Sell	11,977 -100	-0.8%	-$2.99K	0.01%	1372
2013 Q2	$325K	Buy	+12,077	New	+$257K	0.01%	1517

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Capstone Asset Management's IONS Position: Q2 2017 in Review

Capstone Asset Management reduced its Ionis Pharmaceuticals (IONS) stake by 2.5% in Q2 2017, selling an estimated $6.05K and leaving 5,018 shares worth $255K. The position accounts for 0.01% of the portfolio, ranked #1376.

Capstone Asset Management first reported a position in IONS in Q2 2013 and has held it in 7 quarters since. The position peaked at $450K in Q3 2013. 293 funds tracked by Wall St. Rank hold IONS as of Q2 2017.

Capstone Asset Management held 5,018 shares of Ionis Pharmaceuticals worth $255K as of Q2 2017.
Capstone Asset Management sold 130 Ionis Pharmaceuticals shares in Q2 2017, an estimated $6.05K.
Ionis Pharmaceuticals made up 0.01% of Capstone Asset Management's portfolio in Q2 2017, its #1376 holding.
Capstone Asset Management first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 7 quarters since.
Capstone Asset Management's Ionis Pharmaceuticals position peaked at $450K in Q3 2013.
293 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.